Clinical Trial Detail

NCT ID NCT04164979
Title Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, Irvine
Indications

gastroesophageal adenocarcinoma

gastric adenocarcinoma

Therapies

Cabozantinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.